Literature DB >> 18237360

Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program.

Jeonghoon Ahn1, Jeffrey S McCombs, Changun Jung, Tim J Croudace, David McDonnell, Haya Ascher-Svanum, Eric T Edgell, Lizheng Shi.   

Abstract

OBJECTIVES: This study identifies latent classes defined by varying degrees of adherence to antipsychotic drug therapy and examines the sociodemographic, clinical, and resource utilization correlates associated with membership in each adherence class. DATA AND METHODS: Patient-level data were drawn from the 1994 to 2003, 100%-sample California Medicaid fee-for-service paid claims data for patients with schizophrenia (N = 36,195). The date of the first antipsychotic medication filled after January 1, 1999 was then used to divide each patient's data into a 6-month preindex (baseline) and a 12-month postindex (follow-up) period. Three categorical adherence indicators-a dichotomous variable of medication possession ratio greater than 0.80, the number of antipsychotic treatment attempts, and time to a change in antipsychotic medications-and two covariates-a categorical variable of duration of therapy and a dichotomous variable of polypharmacy-were used in the latent class model.
RESULTS: A three-class model returned the lowest values for all the information criteria and was therefore interpreted as follows: The prevalence rates of the latent classes were 1) 14.8% for the adherent; 2) 20.7% for the partially adherent; and 3) 64.5% for the nonadherent. Membership in the nonadherent class was associated with minority ethnicity, being female, eligibility due to welfare status, prior hospitalizations, and a higher number of prior treatment episodes. Membership in the partially adherent class was associated with higher use of outpatient care, higher rates of depot antipsychotic drug use, and polypharmacy.
CONCLUSION: Multiple indicators of adherence to antipsychotic medication can be used to define classes of adherence that are associated with patient characteristics and distinct patterns of prior health-care use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18237360     DOI: 10.1111/j.1524-4733.2007.00214.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  24 in total

1.  Substance use, mental illness, and familial conflict non-negotiation among HIV-positive African-Americans: latent class regression and a new syndemic framework.

Authors:  Allysha C Robinson; Amy R Knowlton; Andrea C Gielen; Joseph J Gallo
Journal:  J Behav Med       Date:  2015-08-22

2.  Effectiveness of sulpiride in adult patients with schizophrenia.

Authors:  Edward Chia-Cheng Lai; Chia-Hsien Chang; Yea-Huei Kao Yang; Swu-Jane Lin; Chia-Yin Lin
Journal:  Schizophr Bull       Date:  2012-02-07       Impact factor: 9.306

Review 3.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

4.  Does Non-Adherence Increase Treatment Costs in Schizophrenia?

Authors:  Mark Pennington; Paul McCrone
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

5.  Comparison of immigrant and native-born population adherence to antipsychotic treatment in a Spanish health region.

Authors:  Irene Forcada; Vanessa Pera; Inés Cruz; Josep Pifarre; Pifarré Josep; Catalina Serna; Montserrat Rué; Leonardo Galván
Journal:  Community Ment Health J       Date:  2012-09-29

6.  Identification of Cross-sector Service Utilization Patterns Among Urban Medicaid Expansion Enrollees.

Authors:  Peter J Bodurtha; Tyler Winkelman; Katherine D Vickery; Ross Owen; Renee Van Siclen; Erik Erickson; Courtney Hougham; Mark Legler; Latasha Jennings; Nathan Shippee
Journal:  Med Care       Date:  2019-02       Impact factor: 2.983

7.  The effect of race-ethnicity on the comparative effectiveness of clozapine among Medicaid beneficiaries.

Authors:  Marcela Horvitz-Lennon; Julie M Donohue; Judith R Lave; Margarita Alegría; Sharon-Lise T Normand
Journal:  Psychiatr Serv       Date:  2013-03-01       Impact factor: 3.084

8.  Indications for and use of long-acting injectable antipsychotics: consideration from an inpatient setting.

Authors:  Taishiro Kishimoto; Sohag Sanghani; Mark J Russ; Akeem N Marsh; Joshua Morris; Suparna Basu; Majnu John; John M Kane
Journal:  Int Clin Psychopharmacol       Date:  2017-05       Impact factor: 1.659

9.  An analysis of electronically monitored adherence to antiretroviral medications.

Authors:  George J Knafl; Carol A Bova; Kristopher P Fennie; Jean P O'Malley; Kevin D Dieckhaus; Ann B Williams
Journal:  AIDS Behav       Date:  2008-12-24

10.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.